Table of Contents
December 01, 2001; Volume 68, Issue 12-
From the Editor
-
Bioterrorism: An unintended boost to public health?
John D. Clough, MD- Cleveland Clinic Journal of Medicine December 2001, 68 (12) 971;
If anything good comes of recent events, it might be rejuvination of America’s public health system, which has languished in recent years.
-
-
The Clinical Picture
-
A 62-year-old man with an abnormal electrocardiogram
Marc Williams, MD and Curtis M. Rimmerman, MD- Cleveland Clinic Journal of Medicine December 2001, 68 (12) 975-976;
Questions and answers on the visible signs of diseases.
-
-
Review
-
Our new understanding of pulmonary alveolar proteinosis: What an internist needs to know
Peter Mazzone, MD, Mary Jane Thomassen, PhD and Mani Kavuru, MD- Cleveland Clinic Journal of Medicine December 2001, 68 (12) 977-993;
Recent advances point to a defect in granulocyte-macrophage colony stimulating factor (GM-CSF) as a cause of this disease. New treatments are under study.
-
-
1-Minute Consult
-
When should central venous catheters be changed in the intensive care unit? Should there be a rigid time-based protocol for doing so?
Stephen A. Mette, MD- Cleveland Clinic Journal of Medicine December 2001, 68 (12) 994-996;
The decision is made case by case rather than on a time-based protocol. Proactive strategies can reduce the risk of infection.
-
-
Editorial
-
Bioterrorism: What practicing physicians can do
James C. Pile, MD and David L. Longworth, MD- Cleveland Clinic Journal of Medicine December 2001, 68 (12) 998-1000;
Given the specter of biological terrorism, the medical system has much to learn and much to do to prepare.
-
-
Review
-
Biological and chemical terrorism: Recognition and management
Thomas P. Noeller, MD- Cleveland Clinic Journal of Medicine December 2001, 68 (12) 1001-1016;
Future terrorist attacks might involve a variety of chemical or biological agents, including nerve agents, blistering agents, hydrogen cyanide, ricin, anthrax, smallpox, plague, and botulinum toxin. Physicians are on the front line.
-
-
Interpreting Key Trials
-
GP IIb/IIIa inhibitors in coronary artery disease management: What the latest trials tell us
Derek P. Chew, MBBS and David J. Moliterno, MD- Cleveland Clinic Journal of Medicine December 2001, 68 (12) 1017-1023;
Recent trials addressed whether there are clinical differences among these drugs, whether their empiric use is justified in acute coronary syndromes, and whether they might allow for early invasive management in acute coronary syndromes.
-
-
Departments
-
Index to Volume 68
- Cleveland Clinic Journal of Medicine December 2001, 68 (12) 1024-1028;
-
